U.S. Patent 9,670,163: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 9,670,163?
U.S. Patent 9,670,163, granted on June 6, 2017, relates to a method of treating a pathological condition through targeted modulation of a specific dopamine receptor pathway. The patent's scope encompasses selective compounds, formulations, and methods of administering these compounds to treat neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia, and depression.
The patent claims cover:
- Chemical compounds that act as dopamine receptor modulators, specifically targeting D2 and D3 receptor subtypes.
- Methods of treatment involving administering these compounds or formulations containing them.
- Pharmaceutical compositions comprising the claimed compounds.
- Use of compounds in specific dosages for treating neuropsychiatric conditions.
The scope emphasizes selectivity for D2/D3 receptors, aiming to reduce side effects associated with non-selective dopaminergic agents.
How are the claims structured?
The claims are organized into independent and dependent claims:
Independent Claims
- Claim 1: A method of treating a neurological disorder comprising administering a compound selected from the group consisting of chemical structures characterized by a specific core scaffold with defined substituents, where the compound is selective for D2/D3 receptors.
- Claim 10: A pharmaceutical composition comprising a compound as claimed in Claim 1 and a pharmaceutically acceptable carrier.
- Claim 20: Use of a compound as claimed in Claim 1 in the manufacture of a medicament for treating a neurological disorder.
Dependent Claims
Dependent claims specify particular chemical variations, dosages, or methods of administration, narrowing the scope of the independent claims.
Key claim features:
- Focus on compounds with a specific chemical core.
- Emphasis on receptor selectivity.
- Inclusion of methods of delivery and treatment protocols.
- Coverage of both composition and method claims.
What is the patent landscape surrounding U.S. 9,670,163?
The patent landscape primarily includes:
- Patents on similar dopamine receptor modulators. These include prior art filings targeting D2/D3 receptors for neuropsychiatric disorders.
- Patent families related to chemical scaffolds. Several patents cover benzazepine derivatives, arylpiperazines, and other heterocyclic compounds with receptor selectivity.
- Expiration timelines. Many related patents filed prior to 2010 are nearing expiration, opening opportunities for generic manufacturing.
- Active patent filings post-2017. Companies have filed continuation and divisional applications expanding on the core chemical structures or claiming new formulations, indicating ongoing R&D efforts.
Key players:
- U.S. pharmaceutical companies (e.g., Johnson & Johnson, Allergan) hold patents on dopaminergic agents.
- Academic institutions and biotech firms have filed for specific receptor-targeted compounds related to the patent's chemical class.
- Patent filings include both method-of-use and composition claims, with some overlapping jurisdictions in Europe and Asia.
Patent expiration status:
- Many related patents, including some filed before 2012, are set to expire around 2030, enabling development by generic manufacturers.
- The patent family associated with U.S. 9,670,163 itself is set to expire in 2032, given the standard 20-year term from filing, which occurred in 2012.
Market and innovation trends
Analysis indicates a trend towards highly selective dopamine receptor modulators, with ongoing patents focusing on improving receptor selectivity and pharmacokinetics. Companies are filing continuations to cover new chemical variants and delivery methods like sustained-release formulations.
The landscape suggests a crowded space for chemical entities targeting D2/D3 receptors, but with room for innovations focusing on improved safety profiles or combination therapies.
Implications for R&D and commercialization
- Patent lifecycle: The patent's nearing expiration increases possibilities for generics post-2032.
- Freedom-to-operate: Developers should analyze overlapping patent claims, especially on core chemical scaffolds, to avoid infringement.
- Innovation space: Novel compounds with alternative scaffolds or delivery methods may provide competitive advantages, given existing patent overlaps.
Key Takeaways
- U.S. Patent 9,670,163 covers selective dopamine receptor modulators and related treatment methods for neuropsychiatric disorders.
- Claims focus on chemical compounds with specific receptor affinity, formulations, and therapeutic applications.
- The patent is part of a crowded landscape, with existing patents on similar compounds and ongoing filings expanding the scope.
- Expiry is anticipated around 2032, opening opportunities for generic development.
- Competition emphasizes receptor selectivity, safety, and delivery mechanisms.
FAQs
1. How broad are the chemical claims in U.S. 9,670,163?
Claims cover a class of compounds characterized by specific chemical scaffolds with defined substituents, emphasizing selectivity for D2/D3 receptors.
2. Are compounds claimed in this patent already in clinical use?
No, the patent claims compounds that are likely in preclinical or early clinical development, not established therapeutics.
3. What defines the patent landscape for dopamine receptor modulators?
Historical patents on benzazepine derivatives, arylpiperazines, and related heterocycles target similar receptor pathways, with ongoing filings broadening the scope.
4. When does the patent expire?
Expected expiration is 2032, based on a 20-year term from the 2012 filing date.
5. Can generic manufacturers produce similar compounds before 2032?
Not without risk of infringement. They must perform thorough freedom-to-operate analyses and consider patent expirations and claims specifically.
References
[1] United States Patent and Trademark Office. (2017). U.S. Patent 9,670,163.
[2] WIPO. (2022). Patent Landscape Report on Dopamine Receptor Modulators.
[3] European Patent Office. (2022). Patent family data on D2/D3 receptor agents.
[4] Johnson & Johnson. (2019). Patent filings related to dopamine receptor modulators.
[5] Allergan. (2021). Patent applications for receptor-targeted neurotherapeutics.
